Thymoquinone alleviates the experimental diabetic peripheral neuropathy by modulation of inflammation

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Chen, Long ^a   Li, Bing ^a   Chen, Biqin ^a   Shao, Yiye ^a   Luo, Qiong ^a   Shi, Xiaohong ^a   Chen, Yinghui ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BENZOQUINONE DERIVATIVE; CYCLOOXYGENASE 2; IL1B PROTEIN, RAT; INTERLEUKIN 1BETA; INTERLEUKIN 6; PTGS2 PROTEIN, RAT; THYMOQUINONE;

ANIMAL; CELL LINE; CELL PROLIFERATION; DIABETIC NEUROPATHY; DRUG EFFECT; EXPERIMENTAL DIABETES MELLITUS; MALE; METABOLISM; PATHOLOGY; RAT; SCHWANN CELL; ULTRASTRUCTURE; WISTAR RAT;

ANIMALS; BENZOQUINONES; CELL LINE; CELL PROLIFERATION; CYCLOOXYGENASE 2; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEUROPATHIES; INTERLEUKIN-1BETA; INTERLEUKIN-6; MALE; RATS; RATS, WISTAR; SCHWANN CELLS;

EID: 84983268342     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep31656     Document Type: Article

References (42)

1. Guariguata, L. et al. Global estimates of diabetes prevalence for 2013 and projections for 2035. Diabetes Res Clin Pract 103, 137-149 (2014).
2. Farmer, K. L., Li, C. & Dobrowsky, R. T. Diabetic peripheral neuropathy: should a chaperone accompany our therapeutic approach? Pharmacol Rev 64, 880-900 (2012).
3. Tesfaye, S. & Selvarajah, D. Advances in the epidemiology, pathogenesis and management of diabetic peripheral neuropathy. Diabetes Metab Res Rev 28 Suppl 1, 8-14 (2012).
4. Ewing, D. J., Campbell, I. W. & Clarke, B. F. Mortality in diabetic autonomic neuropathy. Lancet 1, 601-603 (1976).
5. Vileikyte, L. et al. The development and validation of a neuropathy- and foot ulcer-specific quality of life instrument. Diabetes Care 26, 2549-2555 (2003).
6. Yasuda, H. et al. Diabetic neuropathy and nerve regeneration. Prog Neurobiol 69, 229-285 (2003).
7. Chan, L., Terashima, T., Urabe, H., Lin, F. & Kojima, H. Pathogenesis of diabetic neuropathy: bad to the bone. Ann N Y Acad Sci 1240, 70-76 (2011).
8. Das, A. & Mukhopadhyay, S. The evil axis of obesity, inflammation and type-2 diabetes. Endocr Metab Immune Disord Drug Targets 11, 23-31 (2011).
9. Agrawal, N. K. & Kant, S. Targeting inflammation in diabetes: Newer therapeutic options. World J Diabetes 5, 697-710 (2014).
10. Shi, X., Chen, Y., Nadeem, L. & Xu, G. Beneficial effect of TNF-alpha inhibition on diabetic peripheral neuropathy. J Neuroinflammation 10, 69 (2013).
11. Lee, K. A., Jin, H. Y., Baek, H. S. & Park, T. S. The protective effects of DA-9801 (Dioscorea extract) on the peripheral nerves in streptozotocin-induced diabetic rats. J Nutr Sci Vitaminol (Tokyo) 59, 437-446 (2013).
12. Kawada, N. et al. Towards developing new strategies to reduce the adverse side-effects of nonsteroidal anti-inflammatory drugs. Clin Exp Nephrol 16, 25-29 (2012).
13. Ragheb, A. et al. The protective effect of thymoquinone, an anti-oxidant and anti-inflammatory agent, against renal injury: a review. Saudi J Kidney Dis Transpl 20, 741-752 (2009).
14. Kaseb, A. O. et al. Androgen receptor and E2F-1 targeted thymoquinone therapy for hormone-refractory prostate cancer. Cancer Res 67, 7782-7788 (2007).
15. Salem, M. L. Immunomodulatory and therapeutic properties of the Nigella sativa L. seed. Int Immunopharmacol 5, 1749-1770 (2005).
16. Banerjee, S. et al. Antitumor activity of gemcitabine and oxaliplatin is augmented by thymoquinone in pancreatic cancer. Cancer Res 69, 5575-5583 (2009).
17. Al, W. R. Nigella sativa and thymoquinone suppress cyclooxygenase-2 and oxidative stress in pancreatic tissue of streptozotocininduced diabetic rats. Pancreas 42, 841-849 (2013).
18. Kanter, M. Protective effects of thymoquinone on streptozotocin-induced diabetic nephropathy. J Mol Histol 40, 107-115 (2009).
19. Kanter, M. Effects of Nigella sativa and its major constituent, thymoquinone on sciatic nerves in experimental diabetic neuropathy. Neurochem Res 33, 87-96 (2008).
20. Mehra, M., Merchant, S., Gupta, S. & Potluri, R. C. Diabetic peripheral neuropathy: resource utilization and burden of illness. J Med Econ 17, 637-645 (2014).
21. Satoh, J., Yagihashi, S. & Toyota, T. The possible role of tumor necrosis factor-alpha in diabetic polyneuropathy. Exp Diabesity Res 4, 65-71 (2003).
22. Sango, K. et al. High glucose-induced activation of the polyol pathway and changes of gene expression profiles in immortalized adult mouse Schwann cells IMS32. J Neurochem 98, 446-458 (2006).
23. Lehmann, H. C. & Hoke, A. Schwann cells as a therapeutic target for peripheral neuropathies. CNS Neurol Disord Drug Targets 9, 801-806 (2010).
24. Wang, L. et al. Phosphodiesterase-5 is a therapeutic target for peripheral neuropathy in diabetic mice. Neuroscience 193, 399-410 (2011).
25. Zhang, J., Zhong, H. B., Lin, Y., Yao, W. & Huang, J. Y. KLF15 suppresses cell proliferation and extracellular matrix expression in mesangial cells under high glucose. Int J Clin Exp Med 8, 20330-20336 (2015).
26. Wu, J. H. et al. MiR-18b suppresses high-glucose-induced proliferation in HRECs by targeting IGF-1/IGF1R signaling pathways. Int J Biochem Cell Biol 73, 41-52 (2016).
27. Wang, X., Shi, L., Han, Z. & Liu, B. Follistatin-like 3 suppresses cell proliferation and fibronectin expression via p38MAPK pathway in rat mesangial cells cultured under high glucose. Int J Clin Exp Med 8, 15214-15221 (2015).
28. Gumy, L. F., Bampton, E. T. & Tolkovsky, A. M. Hyperglycaemia inhibits Schwann cell proliferation and migration and restricts regeneration of axons and Schwann cells from adult murine DRG. Mol Cell Neurosci 37, 298-311 (2008).
29. Syroid, D. E. et al. Cell death in the Schwann cell lineage and its regulation by neuregulin. Proc Natl Acad Sci USA 93, 9229-9234 (1996).
30. Eckersley, L. Role of the Schwann cell in diabetic neuropathy. Int Rev Neurobiol 50, 293-321 (2002).
31. Fukunaga, M. et al. Methylglyoxal induces apoptosis through oxidative stress-mediated activation of p38 mitogen-activated protein kinase in rat Schwann cells. Ann N Y Acad Sci 1043, 151-157 (2005).
32. Grober, U., Kisters, K. & Schmidt, J. Neuroenhancement with vitamin B12-underestimated neurological significance. Nutrients 5, 5031-5045 (2013).
33. Gan, L. et al. Restorative effect and mechanism of mecobalamin on sciatic nerve crush injury in mice. Neural Regen Res 9, 1979-1984 (2014).
34. Kellogg, A. P., Cheng, H. T. & Pop-Busui, R. Cyclooxygenase-2 pathway as a potential therapeutic target in diabetic peripheral neuropathy. Curr Drug Targets 9, 68-76 (2008).
35. Lee, J. S. et al. EC-SOD induces apoptosis through COX-2 and galectin-7 in the epidermis. J Dermatol Sci 65, 126-133 (2012).
36. Kim, Y. J., Kim, Y. A. & Yokozawa, T. Pycnogenol modulates apoptosis by suppressing oxidative stress and inflammation in high glucose-treated renal tubular cells. Food Chem Toxicol 49, 2196-2201 (2011).
37. Kellogg, A. P. et al. Protective effects of cyclooxygenase-2 gene inactivation against peripheral nerve dysfunction and intraepidermal nerve fiber loss in experimental diabetes. Diabetes 56, 2997-3005 (2007).
38. Cavieres, V., Valdes, K., Moreno, B., Moore-Carrasco, R. & Gonzalez, D. R. Vascular hypercontractility and endothelial dysfunction before development of atherosclerosis in moderate dyslipidemia: role for nitric oxide and interleukin-6. Am J Cardiovasc Dis 4, 114-122 (2014).
39. Russell, J. W., Sullivan, K. A., Windebank, A. J., Herrmann, D. N. & Feldman, E. L. Neurons undergo apoptosis in animal and cell culture models of diabetes. Neurobiol Dis 6, 347-363 (1999).
40. Russell, J. W. et al. High glucose-induced oxidative stress and mitochondrial dysfunction in neurons. FASEB J 16, 1738-1748 (2002).
41. Schmeichel, A. M., Schmelzer, J. D. & Low, P. A. Oxidative injury and apoptosis of dorsal root ganglion neurons in chronic experimental diabetic neuropathy. Diabetes 52, 165-171 (2003).
42. Chang, X. Z. et al. Identification of the functional role of peroxiredoxin 6 in the progression of breast cancer. Breast Cancer Res 9, R76 (2007).